Sugi Predict

Sugi Predict / Compounds / SCHEMBL17464347

SCHEMBL17464347

SCHEMBL17464347

COC(=O)c1cc(B(O)O)ccc1OC

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.46
▸ GAA P10253 2/20 0.45
▸ EGFR P00533 1/20 0.44
▸ KMT2A Q03164 3/20 0.43
▸ MAPT P10636 5/20 0.43
▸ HPGD P15428 4/20 0.43
▸ LMNA P02545 2/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ TSHR P16473 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ HSP90AA1 P07900 2/20 0.43
▸ HTT P42858 2/20 0.43
▸ NPSR1 Q6W5P4 2/20 0.43
▸ POLB P06746 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ ENPP2 Q13822 2/20 0.41
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL189207 0.86 KDM4E (0.46) KDM4EGAAKMT2AMAPTHPGD
SCHEMBL20943078 0.84 HTT (0.46) KDM4EGAAKMT2AMAPTHPGD
SCHEMBL29955154 0.84 KDM4E (0.50) KDM4EMAPTHPGDLMNAHSD17B10
SCHEMBL1163265 0.84 KDM4E (0.50) KDM4EMAPTHPGDLMNAHSD17B10
SCHEMBL9110483 0.84 CA1 (0.47) KDM4EGAAMAPTHPGDLMNA
SCHEMBL2825641 0.81 CA12 (0.62) KDM4EGAAEGFRKMT2AMAPT
SCHEMBL15516681 0.81 CA2 (0.41) KDM4EGAAMAPTHPGDLMNA
SCHEMBL29952002 0.81 CA12 (0.62) KDM4EGAAEGFRKMT2AMAPT
SCHEMBL18593627 0.79 TTBK1 (0.40) KDM4EGAAKMT2AMAPTHPGD
SCHEMBL237491 0.79 ALDH1A1 (0.43) KDM4EGAAKMT2AMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250353851-A1 PURINES AND METHODS OF THEIR USE KINETA INC (US) 2025-11-20 — — US disclosed
US-20250221966-A1 RXFP1 AGONISTS BRISTOL MYERS SQUIBB CO (US) 2025-07-10 — — US disclosed
WO-2025077841-A1 AMIDE-SUBSTITUTED CYCLOALKYL COMPOUNDS, PREPARATION METHOD THEREFOR AND MEDICAL USES THEREOF 江苏恒瑞医药股份有限公司 2025-04-17 — — WO disclosed
CN-119137112-A Quinoline cGAS antagonist compounds 免疫传感器治疗股份有限公司 2024-12-13 — — CN disclosed
CN-119031913-A Purine and methods of use thereof 奇尼塔公司 2024-11-26 — — CN disclosed
CN-118843613-A RXFP1 agonists 百时美施贵宝公司 2024-10-25 — — CN disclosed
EP-4448508-A1 BENZOTHIOPHENE DERIVATIVES AS RXFP1 AGONISTS Bristol-Myers Squibb Company (US) 2024-10-23 — — EP disclosed
EP-4444312-A2 PURINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2024-10-16 — — EP disclosed
CN-118647606-A Benzothiophene derivatives as RXFP1 agonists 百时美施贵宝公司 2024-09-13 — — CN disclosed
EP-4422746-A1 RXFP1 AGONISTS Bristol-Myers Squibb Company (US) 2024-09-04 — — EP disclosed
WO-2021203023-A1 INDOLE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED (US) 2021-10-07 — — WO disclosed
WO-2020201305-A1 4-(2,4-BIS(2-HYDROXYPHENYL)-1H-IMIDAZOL-1-YL)BENZOIC ACID DERIVATIVES AS NOVEL IRON CHELATORS VIFOR (INTERNATIONAL) AG (CH) 2020-10-08 — — WO disclosed
US-20200291002-A1 BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C BRISTOL MYERS SQUIBB CO (US) 2020-09-17 — — US disclosed
EP-3209664-B1 BICYCLIC HETEROARYL AMINE COMPOUNDS AS PI3K INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2020-06-03 — — EP disclosed
CN-107286166-B Substituted 1,3,4, 5-tetrahydro-6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one derivatives 上海勋和医药科技有限公司 2020-03-31 — — CN disclosed
US-20170355707-A1 BICYCLIC HETEROARYL AMINE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2017-12-14 — — US disclosed
WO-2017165233-A1 BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2017-09-28 — — WO disclosed
EP-3209664-A1 BICYCLIC HETEROARYL AMINE COMPOUNDS AS PI3K INHIBITORS Bristol-Myers Squibb Company (US) 2017-08-30 — — EP disclosed
US-20160024103-A1 FUSED FURANS FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY 2016-01-28 — — US disclosed
US-20160024103-A1 FUSED FURANS FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY 2016-01-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355707-A1 BICYCLIC HETEROARYL AMINE COMPOUNDS PIK3R3, JAK2, JAK3 KDM4E 2233/4885GAA 4584/4885EGFR 1567/4885
US-20200291002-A1 BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C HAVCR2, UGT2B7, GOT1 KDM4E 3114/4885GAA 480/4885EGFR 3664/4885
US-20250221966-A1 RXFP1 AGONISTS RXFP1, RXFP2, RXFP3 KDM4E 3426/4885GAA 2587/4885EGFR 303/4885
US-20160024103-A1 FUSED FURANS FOR THE TREATMENT OF HEPATITIS C HAVCR2, HCCS, GOT1 KDM4E 4204/4885GAA 1059/4885EGFR 2735/4885
US-20250353851-A1 PURINES AND METHODS OF THEIR USE TDP1, TDP2, PIKFYVE KDM4E 870/4885GAA 745/4885EGFR 4739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.